Q1 Was Slow For Deals, But That Could Change With One Big Transaction – PwC

Life science deal-making declined by volume during the first quarter, but aggregate value was up. Looking ahead, PwC sees an ideal environment for major deals – if something like Takeda/Shire sparks a trend.